Psychology School, Hochschule Fresenius, University of Applied Sciences, Infanteriestraße 11a, 80797, Munich, Germany.
Department of Gynecology, Breast Center, Rotkreuzklinikum, Munich, Germany.
Breast Cancer Res Treat. 2021 Jul;188(2):351-359. doi: 10.1007/s10549-021-06195-7. Epub 2021 Mar 31.
This study examines congruence between self-reported and device-measured physical activity data in women with early breast cancer and compares trajectories under different treatments.
Women with non-metastatic breast cancer were recruited before primary therapy. In four weeks distributed over six months after treatment start, patients reported time spent on work, transport, chores and sports via diary and wore Garmin vivofit 3 accelerometers to assess steps taken. Associations between these measures and agreement regarding guideline adherence were tested with Spearman's Correlation Coefficient and Weighted Kappa statistic. Effects of time and treatment were evaluated using mixed analyses of variance.
Ninety-nine participants (median age = 50) were treated with adjuvant (N = 23), neoadjuvant (N = 21) or without chemotherapy (N = 55). Coherence between self-report and device data was strong (r = 0.566). Agreement about reaching recommendations was only "fair" (kappa coefficient = 0.321 and 0.249, resp.). Neither treatment or week nor their interaction had effects on step counts (all p > 0.05). Self-reported activity time was lower for patients with chemotherapy than for those without (adjuvant: ∆ = 69min, p = 0.006, neoadjuvant: ∆ = 45min, p = 0.038) and lower in week 18 than in week 3 (∆ = 43min, p = 0.010).
Results show that consumer-grade activity monitors and self-reports correlate but show different perspectives on physical activity in breast cancer patients. In general, patients perceive some decline regardless of primary treatment regimen. Those affected should be offered assistance to gain the benefits of activity. Accelerometers may help professionals to identify these individuals and patients to verify appraisal of their activity levels.
本研究旨在探讨早期乳腺癌女性自我报告和设备测量的身体活动数据之间的一致性，并比较不同治疗下的轨迹。
在原发治疗前招募患有非转移性乳腺癌的女性。在治疗开始后六个月内的四周内，患者通过日记报告工作、交通、家务和运动时间，并佩戴 Garmin vivofit 3 计步器来评估所走步数。使用 Spearman 相关系数和加权 Kappa 统计检验这些措施之间的关联和对指南依从性的一致性。使用混合方差分析评估时间和治疗的影响。
99 名参与者（中位数年龄=50 岁）接受辅助治疗（N=23）、新辅助治疗（N=21）或无化疗治疗（N=55）。自我报告和设备数据之间的一致性很强（r=0.566）。关于达到建议的一致性仅为“一般”（kappa 系数分别为 0.321 和 0.249）。治疗或周数及其相互作用对步数均无影响（均 p>0.05）。与未接受化疗的患者相比，接受化疗的患者自我报告的活动时间更短（辅助治疗：∆=69min，p=0.006，新辅助治疗：∆=45min，p=0.038），且第 18 周比第 3 周更低（∆=43min，p=0.010）。
结果表明，消费级活动监测器和自我报告相关，但对乳腺癌患者身体活动的看法不同。一般来说，无论主要治疗方案如何，患者都会感到一些下降。应向受影响的患者提供帮助，以获得活动的益处。加速度计可帮助专业人员识别这些个体，也可帮助患者验证其活动水平的评估。
